Tumour immunology - Tumour-induced immune modulation of sentinel lymph nodes

被引:203
作者
Cochran, Alistair J. [1 ]
Huang, Rong-Rong
Lee, Jonathan
Itakura, Eijun
Leong, Stanley P. L.
Essner, Richard
机构
[1] Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Surg Oncol, Inst Canc, New Brunswick, NJ 08901 USA
[3] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[4] John Wayne Canc Inst, Dept Surg Oncol, Santa Monica, CA 90404 USA
[5] John Wayne Canc Inst, Dept Mol Therapeut, Santa Monica, CA 90404 USA
关键词
D O I
10.1038/nri1919
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sentinel lymph nodes (SLNs), being the first nodes to receive lymph from a primary tumour and the preferential site of initial tumour metastases, are intensively exposed to the bioactive products of tumour cells and other associated cells. This makes them ideal for studies of the factors that determine selective tissue susceptibility to metastases. We postulate that tumour-induced immune modulation of SLNs facilitates lymph-node metastases by inhibiting the generation of tumour-specific cytotoxic T cells that are active against tumour cells of primary and metastatic melanomas. Immune modulation of the lymph nodes can be reversed by granulocyte/macrophage colony-stimulating factor (GM-CSF), a finding that has implications for the future therapy of lymph-node metastases.
引用
收藏
页码:659 / 670
页数:12
相关论文
共 122 条
[91]   Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer [J].
Sakakura, K ;
Chikamatsu, K ;
Sakurai, T ;
Takahashi, K ;
Murata, T ;
Oriuchi, N ;
Furuya, N .
ORAL ONCOLOGY, 2005, 41 (01) :89-96
[92]   Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate [J].
Salcedo, M ;
Bercovici, N ;
Taylor, R ;
Vereecken, P ;
Massicard, S ;
Duriau, D ;
Vernel-Pauillac, F ;
Boyer, A ;
Baron-Bodo, V ;
Mallard, E ;
Bartholeyns, J ;
Goxe, B ;
Latour, N ;
Leroy, S ;
Prigent, D ;
Martiat, P ;
Sales, F ;
Laporte, M ;
Bruyns, C ;
Romet-Lemonne, JL ;
Abastado, JP ;
Lehmann, F ;
Velu, T .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (07) :819-829
[93]   CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-ζ chain expression [J].
Schüle J.M. ;
Bergkvist L. ;
Håkansson L. ;
Gustafsson B. ;
Håkansson A. .
Journal of Translational Medicine, 2 (1)
[94]   Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4+ T-regulatory cells and systemic collapse of antitumour immunity [J].
Seo, N ;
Hayakawa, S ;
Takigawa, M ;
Tokura, Y .
IMMUNOLOGY, 2001, 103 (04) :449-457
[95]  
Shackleton Mark, 2004, Cancer Immun, V4, P9
[96]   Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF [J].
Si, Z ;
Hersey, P ;
Coates, AS .
MELANOMA RESEARCH, 1996, 6 (03) :247-255
[97]  
Snow HM, 1892, Lancet, V140, P869
[98]   Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells [J].
Steinbrink, K ;
Jonuleit, H ;
Müller, G ;
Schuler, G ;
Knop, J ;
Enk, AH .
BLOOD, 1999, 93 (05) :1634-1642
[99]   CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity [J].
Steinbrink, K ;
Graulich, E ;
Kubsch, S ;
Knop, J ;
Enk, AH .
BLOOD, 2002, 99 (07) :2468-2476
[100]   Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes [J].
Straten, PT ;
Dahl, C ;
Schrama, D ;
Pedersen, LO ;
Andersen, MH ;
Seremet, T ;
Bröcker, EB ;
Guldberg, P ;
Becker, JC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (05) :495-502